Immunotherapy

Patients with food allergies can avoid items that may be dangerous — or they can work with an allergist to develop an oral immunotherapy plan that would enable them to safely consume and enjoy previously dangerous foods.

Therapeutic immunomodulation with a sublingual mucosal bacterial vaccine in adults with COPD reduced the number and length of exacerbations and antibiotic use, researchers reported at the European Respiratory Society International Congress.

National Comprehensive Cancer Network updated its guidance on COVID-19 vaccination for patients with cancer following FDA authorization of a third mRNA vaccine dose for certain immunocompromised individuals.

Awareness of oral immunotherapy for food allergy appeared low among those affected and pediatric caregivers, according to survey results published in The Journal of Allergy and Clinical Immunology: In Practice.

In this episode, Kevin C. Soares, MD, discusses his path to GI oncology, how immune therapy complements surgical interventions, and shares his thoughts on how the pandemic will impact medical practices.

Continued daily treatment with Peanut Allergen Powder-dnfp after its first year improves safety and tolerability profiles, as well as clinical and immunological responses, according to a study published in Allergy.

David R. Gandara, MD, summarized a crossfire panel from the International Lung Cancer Congress where experts discussed use of immunotherapy-containing regimens in the frontline setting for patients with advanced-stage non-small cell lung cancer.

Antihistamine premedication can improve the safety and efficacy of allergen immunotherapy, according to results of a meta-analysis published in Annals of Allergy, Asthma & Immunology.

Results from a small study showed that an odor-based tool identified ovarian cancer with 95% accuracy and pancreatic cancer with 90% accuracy. A report on the data was the top story in hematology/oncology last week.

In this video, Janos L. Tanyi, MD, PhD, discussed findings from the “very interesting” VITAL study that assessed the potential of a novel vaccine as front-line maintenance therapy for women with ovarian cancer.